The Hippo signaling pathway is an evolutionarily conserved kinase cascade, playing multiple 28 roles in embryonic development that controls organ size, cell proliferation and apoptosis. At the 29 center of this network lie the Hippo kinase target and downstream pathway effector Yes-30 associated protein (YAP) and its paralog TAZ. In its phosphorylated form, cytoplasmic YAP is 31 sequestered in an inactive state. When it is dephosphorylated, YAP a potent oncogene, is 32 activated and relocates to the nucleus to interact with a number of transcription factors and 33 signaling regulators that promote cell growth, differentiation and survival. The identification of 34 YAP activation in human cancers has made it an attractive target for chemotherapeutic drug 35 
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Introduction:
pathway target YAP or TAZ in the cytoplasm (19, 25, 46, 75) . In this sense an "active" Hippo 77 pathway is one in which YAP/TAZ are phosphorylated in an inactive state in the cytoplasm. An 78 "inactive" pathway is one where YAP/TAZ are dephosphorylated and expressed in the nucleus 79 where they bind one of four TEAD transcription factors (TEAD1-4). The YAP/TAZ-TEAD 80 transcription complex in turn mediates context-dependent transcriptional gene expression such 81
as CTGF and others involved in cell survival, cell polarity and cell fate determination (74, (77) (78) (79) . 82
Several components of the pathway have been implicated in mammalian models of 83 tumorigenesis. Nf2 is a tumor suppressor gene responsible for neurofibromatosis type II. Nf2 84 loss is associated with a wide range of tumors including osteosarcoma and hepatocellular 85 carcinoma (39). Lats1 deficiency results in soft tissue sarcomas and ovarian tumors (61). Mst 86 deficient mice develop hepatocellular carcinoma, cholangiocarcinoma and colonic adenoma (37, 87 60, 80). Mob1 mutant mice develop skin liver and breast cancer as well as osteosarcomas and 88 fibrosarcomas (44). Yap is an oncogene that is amplified in hepatocellular and squamous cell 89 carcinomas, gastrointestinal dysplasia and pancreatic duct metaplasia (4, 12, 55, 73) . 90 A crucial step in urinary tract maturation is the movement of the ureter from its initial branch 127 point on the nephric duct (ND) to its final insertion site in the cloaca (primitive bladder and 128 urethra) (10, 45) . Mutations in the tyrosine kinase receptor Ret result in delay or failure of the 129 ND to insert into the cloaca (10). Approximately 5% of living patients with congenital 130 abnormalities of the kidney and urinary tract (CAKUT) harbor mutations in the RET pathway (7 (29, 32, 67) . (14). 180 This study demonstrated that KIBRA interacts with the actin-bundling protein synaptopodin and 181 the cell polarity protein PATJ. The functional impact of these interactions was highlighted by the 182 finding that silencing the Wwc1 gene that encodes KIBRA in human podocytes resulted in 183 impaired directed migration based on the reduced ability of knockdown podocytes to close a 184 wound in a wound-healing assay (14). Despite increased velocity the KIBRA-knockdown 185 podocytes had impaired polarity that disrupted their capacity for directed cell migration. Further 186 studies will be needed to clarify the role of KIBRA in the context of podocyte actin cytoskeleton 187 integrity and its interaction with modulators of podocyte motility and polarity (15, 71) . of PKD-associated genes that have also been linked to the renal ciliary system including khd1, 212
Tg737, Kif3a, and well as Tsc1 (tuberous sclerosis complex), which has been associated with 213 glomerular cyst development (24) . 214
The link between Taz deletion and the development of cystic renal disease was further 215 demonstrated with a Taz-null/lacZ knockin mouse (38). These animals also developed cystic 216 renal disease, with cysts mainly derived from glomeruli and proximal tubular epithelia, as well as 217 dilated air spaces in the lung resembling human pulmonary emphysema. As observed in human 218 PKD, these TAZ-null/ lacZ knockin mutants also had urinary concentration defects, polyuria, and 219 hydronephrosis. Interestingly, here there were no changes in expression levels of genes 220 involved in human PKD, including ADPKD (autosomal dominant polycystic kidney disease)-221 associated polycystin-1 (Pkd1) and polycystin-2 (Pkd2), and Pkhd1, which has been linked to 222
ARPKD (autosomal recessive polycystic kidney disease). 223
Taz serves as a transcriptional coactivator of Glis3, a subfamily of Kruppel-like zinc finger 224 proteins that contain a DNA binding domain and regulate gene transcription (2, 28). Similar to 225 proximal and distal tubules and collecting ducts. In addition, Glis3 localized to primary cilia, and 227 a significant number of epithelial cells in renal cysts either lacked primary cilia or had truncated 228 primary cilia. Thus it is possible that TAZ interacts with Glis3 to suppress cyst formation. 229
Another interesting observation lies with the signaling properties of cysts in Taz Hippo pathway, the epidermal growth factor receptor (EGFR) pathway was initially proposed as 266 a target for cancer therapy (54). It has since been implicated in diabetic kidney disease. 267
Prolonged EGFR activation in diabetic animals enhances TGFβ-mediated renal injury, while 268 attenuation of EGFR signaling is protective (8, 47, 50, 53) . A recently published study 269 establishes a link between EGFR and Hippo signaling in the diabetic kidney (9). YAP expression 270 and phosphorylation was found to be increased in animal models of type 1 (streptozosin-271 induced) and type 2 (db/db) diabetes, as well as in proximal tubule-like epithelial cells exposed 272 to high glucose for 24 hrs. These effects were attenuated by in vivo and in vitro silencing of 273 EGFR expression as well as treatment of mice and cells with the EGFR inhibitor, erlotinib. In 274 mice with proximal tubule EGFR deletion, TAZ expression was decreased, indicating differentialto the pathogenesis of diabetic kidney disease was the observation that expression of CTGF 277 and another YAP transcriptional target gene, amphiregulin (AREG), were increased after high-278 glucose treatment. The high-glucose effects on CTGF and AREG were blunted after either 279 EGFR or YAP was silenced by their specific siRNA and also after treatment with vertoporforin, 280 which is an inhibitor of YAP-TEAD interaction (9). These findings suggest that the diabetic milieu 281 promotes differential YAP expression, phosphorylation and target gene expression in an EGFR-282 dependent manner. These findings highlight the potentially deleterious effects of unrestrained YAP signaling and 296 provide further confirmation of crosstalk between the Hippo and EGFR pathways. 297
Renal fibrosis, arising as a result of numerous divergent processes culminates in the deposition 302 of extracellular matrix that classically accompanies chronic kidney disease (23). Stiff 303 extracellular matrix enhances TGFβ induced profibrotic Smad signaling in a process mediated 304 by YAP and TAZ (63) . In the unilateral ureteral obstruction (UUO) model of renal fibrosis, 305 YAP/TAZ display nuclear expression unlike sham-operated controls. Furthermore, Verteporfin a 306 drug that inhibits YAP-TEAD interaction and YAP transcriptional activity reduces interstitial 307 YAP/TAZ staining, associated nuclear Smad 2/3 nuclear accumulation and renal fibrosis (63) . 308
An antibody that recognized both YAP/TAZ was used here, so a distinction cannot be made 309 regarding divergent functions of the two molecules. This study identified a potential therapeutic 310 strategy to target both classic Smad 2/3 and mechanosensitive YAP/TAZ in renal fibrogenesis. 311
312

Conclusion 313
Limited but compelling evidence exists that the Hippo signaling pathway has a significant role in 314 kidney and urinary tract development, podocyte homeostasis, fibrotic, cystic and diabetic kidney 315 disease. In the kidney as in other model systems, the relationship between YAP and its paralog 316 
